ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED 阿里健康信息技術有限公司 （於百慕達註冊成立之有限公司） （股份代號：00241） 提名委員會職權範圍 成員 委員會議事程序 – 1 – 1. 提名委員會（「委員會」）須由阿里健康信息技術有限公司（「本公司」）董事會（「董 事會」）設立，當中成員須以符合《香港聯合交易所有限公司證券上市規則》所規 定的獨立性要求的獨立非執行董事佔大多數。 2. 委員會主席須由董事會任命，並須為董事會主席或委員會內的獨立非執行董 事。 2A. 本公司應為提名委員會委任至少一名不同性別的董事。 3. 本公司的公司秘書或（在其缺席時）其代表應擔任委員會秘書。 4. 董事只有在他們認為自己能按其角色及職責向本公司投入足夠時間並作出貢獻 時，才同意擔任委員會的成員。 5. 委員會每年應最少舉行一次會議。委員會的任何成員或秘書可在必要時隨時召 開會議。 6. 委員會會議所需的法定人數為兩名委員會成員，其中一名必須是獨立非執行董 事。 責任與職責 – 2 – 7. 委員會可邀請以下人士出席委員會會議：(a)本公司高級管理人員和╱或任何其 他董事，及╱ ...

每日晨报│2025 年 8 月 14 日 主要市场指数表现 | | 收市价 | 上个交易日升 | YTD 升跌 | | --- | --- | --- | --- | | 恒生指数 | 25,613 | +2.58% | +27.69% | | 恒生科技指数 | 5,630 | +3.52% | +26.02% | | 国企指数 | 9,150 | +2.62% | +25.52% | | 沪深 300 | 4,176 | +0.79% | +6.14% | | 上证综合指数 | 3,683 | +0.48% | +9.90% | | 深证成份指数 | 11,551 | +1.76% | +10.92% | | 中小板指 | 7,097 | +0.95% | +11.21% | | 道琼斯指数 | 44,922 | +1.04% | +5.59% | | 标普 500 指数 | 6,466 | +0.32% | +9.95% | | 纳斯达克指数 | 21,713 | +0.14% | +12.44% | | 伦敦富时指数 | 9,165 | +0.19% | +12.14% | | CAC40 指数 | 7 ...

Group 1: Macro Strategy and Market Overview - The three major equity indices continued to rise in early August, with the Shanghai Composite Index and Shenzhen Component Index both increasing by over 2%, and the ChiNext Index rising by 4.88% [20][21] - The central bank's net cash injection was 163.5 billion yuan, maintaining stable liquidity in early August, with the 7-day reverse repo rate (DR007) hovering around 1.45% [21][22] - Commodity prices showed mixed trends, with non-ferrous metals rebounding, crude oil slightly declining, and precious metals rebounding again [21] Group 2: Fixed Income and Bond Market - The upcoming issuance of 20-year special government bonds is expected to peak, presenting trading opportunities during the issuance process [2] - The new and old bond yield spread for 20-year bonds typically narrows by 0.4-1.5 basis points, with notable exceptions during significant market events [2] Group 3: Export Growth and Trade Analysis - China's exports showed steady growth in the first seven months of 2025, with a cumulative year-on-year increase of 6.1%, surpassing the 5.8% growth rate for the entire year of 2024 [23][24] - The global trade volume is expected to cool down in the second half of the year, influenced by preemptive demand in the U.S. and a decline in imports [23][24] - China's share of global exports has been increasing, with a notable rise in exports to non-U.S. regions compensating for declines in U.S. exports [24][25] Group 4: Company-Specific Insights - Yuan Da Pharmaceutical achieved a revenue of 10.784 billion yuan in 2024, a year-on-year increase of 10.59%, and a net profit of 2.286 billion yuan, up 31.28% [28][31] - The company is pioneering a new treatment for sepsis, STC3141, which has shown promising results in clinical trials [29][30] - Yuan Da's nuclear medicine segment is expanding, with significant sales growth expected from its core product, yttrium-90 microspheres, which has treated nearly 2,000 patients [30][31] Group 5: Industry Trends and Recommendations - The semiconductor industry is projected to continue its optimistic growth trajectory in 2025, driven by AI and high-performance computing [7] - The demand for storage solutions, particularly HBM and DDR5, is expected to remain strong, with price increases anticipated in the third quarter [7] - The construction materials sector, particularly cement and explosives, is expected to benefit from major infrastructure projects like the New Tibet Railway [34]

Investment Rating - The industry investment rating is "Outperform the Market," indicating an expected industry index increase of over 5% in the next six months [58]. Core Insights - The report highlights the significant advancements in AI applications, particularly with the release of OpenAI's GPT-5, which is expected to accelerate commercialization in various high-frequency, high-value verticals [7][5]. - Companies like Duolingo, Palantir, and AppLovin have reported earnings that exceeded market expectations, showcasing the growing revenue contributions from AI capabilities [7][5]. - The report suggests a focus on companies with high retention rates and growth potential in sectors such as education, e-commerce, advertising, and enterprise data analysis [7][5]. Summary by Sections Key Company Financials - **Palantir**: Q2 revenue reached $1.004 billion, a 48% year-over-year increase, with a GAAP operating income of $269 million and an adjusted gross margin of 82% [14]. - **AMD**: Q2 revenue was $7.685 billion, a 32% year-over-year increase, with a gross margin of 54% and operating income of $897 million [19]. - **AppLovin**: Q2 advertising revenue grew 77% year-over-year to approximately $1.26 billion, with an adjusted EBITDA of $1.02 billion [24]. - **Duolingo**: Q2 revenue reached $252.3 million, a 41% year-over-year increase, with a gross margin of 72.4% [29]. - **Datadog**: Q2 revenue was $827 million, a 28% year-over-year increase, with a gross margin of 80.9% [33]. Global AI Developments - OpenAI launched two new large language models, gpt-oss-120b and gpt-oss-20b, which are open-weight models aimed at enhancing AI application performance [36]. - Google DeepMind introduced Genie 3, a model capable of generating interactive virtual worlds in real-time, marking a significant milestone in world modeling [40]. - Anthropic released Claude Opus 4.1, which shows improvements in coding and reasoning capabilities compared to its predecessor [45]. - OpenAI's GPT-5 was officially released, featuring a significant reduction in hallucination rates and enhanced reasoning capabilities [49].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 （於百慕達註冊成立之有限公司） ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED 阿里健康信息技術有限公司 董事會欣然公佈，於2025年8月8日舉行之股東週年大會上，通告所載之全部決議 案已經股東以投票表決方式正式通過。 茲提述(i)阿里健康信息技術有限公司（「本公司」，連同其附屬公司統稱「本集團」）日 期為2025年7月10日之股東週年大會（「股東週年大會」）通告（「通告」）；及(ii)本公司 日期為2025年7月10日之通函（「通函」）。除文義另有所指外，本公告所用專有詞彙 與通函所界定者具有相同涵義。 股東週年大會結果 本公司董事（「董事」）會（「董事會」）欣然公佈，於2025年8月8日（星期五）上午十時三 十分假座香港銅鑼灣禮頓道8號香港銅鑼灣皇冠假日酒店28樓貴賓廳舉行之股東週 – 1 – （股份代號：00241） 於2025年8月8日舉行之 股東週年 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 致：香港交易及結算所有限公司 公司名稱: 阿里健康信息技術有限公司 (於百慕達註冊成立之有限公司) 呈交日期: 2025年8月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00241 | 說明 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | 20,000,000,000 | HKD | | 0.01 HKD | | 200,000,000 | | 增加 / 減少 (-) | | | 0 | | HKD | | 0 | | 本月底結存 | | 20,000,000,000 | HKD | | 0.01 HKD | | 200,000,000 | 本月底法定/註冊股本總額： HKD 200,000,000 第 1 頁 共 1 ...

截至收盘，中证云计算与大数据主题指数上涨1.2%，中证人工智能主题指数上涨0.5%，国证机器人产业指数下跌0.3%，恒生港股通创新药 指数下跌1.2%，中证新能源指数下跌3.1%。 昨日，阿里健康新推AI医学助手"氢原子"，该助手整合了千万级医学核心期刊文献，支持查阅权威指南、语义搜索、AI总结、全文翻译与 智能问答，可以帮助用户快速找到所需信息，适合临床医学工作者和医学研究者，能高效助力医学学习与科研工作。 | 人工智能ETF W | | | 159819 | | --- | --- | --- | --- | | 跟踪中证人工智能主题指数 | | | | | | | | ·· | | 该指数完整覆盖人工智能 | | | | | 产业链,涵盖上游基建、 | �日 | 该指数 | 该指数自2015年 | | 中游模型、下游应用等环 | 该指数涨跌 | 滚动市盈率 | 发布以来估值分位 | | 节,是人工智能产业的代 | | | | | 表性指数,全面捕捉人工 智能产业未来发展机遇。 | 0.5% | 3.8 F | 52.9% | | 机器人ETF易方达 | | | 159530 | | 跟踪国证机器人产业指 ...

Core Viewpoint - The article discusses the rapid growth and potential of AI in healthcare, highlighting its transformative impact on patient management and the healthcare system in China, while also addressing the challenges and limitations faced by AI technologies in this sector [2][4][10]. Group 1: AI in Healthcare Services - AI services are increasingly being adopted by patients for health management, with applications such as report interpretation and intelligent triage leading the trend [2][3]. - Major internet companies like JD Health, Alibaba Health, and Baidu Health are actively developing independent AI health management applications, indicating a competitive landscape [3][4]. - The AI health management market in China is projected to reach 25.9 trillion yuan by 2027, with a compound annual growth rate exceeding 20% [4]. Group 2: Impact on Traditional Healthcare - AI technologies are significantly changing the traditional healthcare system, allowing hospitals to serve a larger number of patients efficiently [5][10]. - AI can alleviate the burden on healthcare professionals by handling repetitive tasks, thus improving overall service efficiency [7][10]. - The integration of AI into healthcare aims to create a closed-loop system that connects various healthcare services, enhancing data collection and patient management [7][10]. Group 3: Challenges and Limitations - Despite the potential benefits, there are significant challenges in gaining public trust in AI healthcare solutions, with only 3.59% of people believing AI can fully replace doctors [13][14]. - The complexity of integrating AI into healthcare requires deep collaboration with medical professionals to ensure the accuracy and reliability of AI systems [14][15]. - Legal and regulatory challenges, particularly concerning data privacy and the definition of responsibility in AI applications, pose significant hurdles for the industry [15][16].

Core Insights - The Hong Kong pharmaceutical sector is experiencing a strong rally, with the China Securities Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index (930965) rising by 1.50% as of July 16, 2025, driven by significant gains in individual stocks such as Lijun Pharmaceutical (01513) up 11.16% and Green Leaf Pharmaceutical (02186) up 8.55% [1][2] - The introduction of a commercial health insurance innovative drug directory by the National Healthcare Security Administration on July 11, 2025, marks a significant development, allowing for the inclusion of high-innovation drugs that exceed basic insurance coverage [1][2] - The first innovative drug directory involving commercial insurance is expected to be launched within 2025, potentially creating a more favorable pricing environment compared to traditional medical insurance negotiations [2] Industry Summary - The Hong Kong Medical ETF (513700) has seen a 1.72% increase, marking its fourth consecutive rise, with the latest price reported at 0.65 yuan [1] - The index reflects the performance of 50 liquid and large-cap healthcare companies within the Hong Kong Stock Connect, with the top ten weighted stocks accounting for 59.44% of the index [2] - The commercial health insurance sector is anticipated to experience significant growth, with potential for premium and innovative drug payment scales to increase by several multiples in the long term [2]

Group 1 - The Hang Seng Index (HSI) shows a significant rebound, with bullish investors expecting it to rise to 25,000, supported by a recovery price of 24,020 for overnight bull certificates [1] - Alibaba (09988.HK) has potential upward movement, with bullish investors targeting a price of 130 HKD, while the stock closed at 113.5 HKD, reflecting a 6.97% increase [3] - Bilibili-W (09626.HK) has broken through the upper Bollinger Band at 182 HKD, closing at 184.9 HKD, indicating a "buy" signal with resistance levels at 194.5 HKD and 200 HKD [6] Group 2 - NetEase-S (09999.HK) shows signs of a rebound, with a "buy" signal and resistance levels at 216 HKD and 224 HKD, suggesting that options with a strike price around 220 HKD may be more favorable [9] - Sunny Optical Technology (02382.HK) is experiencing upward momentum, closing near the upper Bollinger Band at 76.4 HKD, with a strong buy signal and resistance levels at 78.4 HKD and 82.3 HKD [12] - Alibaba Health (00241.HK) has risen for six consecutive days, with resistance levels at 4.8 HKD and 5.13 HKD, and options with a strike price of 4.51 HKD are considered reasonable [15]